This feature highlights changes in clinical trial organizations’ personnel.

AsclepiX Therapeutics

Robert Dempsey has been named CEO and president of AsclepiX Therapeutics. Formerly, Dempsey was CEO of TearClear.

Aulos Bioscience

Aulos Bioscience has appointed Aron Knickerbocker CEO of the company. Knickerbocker previously served as founding CEO of RayzeBio.

Be Biopharma

Joanne Smith-Farrell has been named CEO of Be Biopharma. Previously, Smith-Farrell was bluebird bio’s chief operating officer and business unit head of oncology. Be Biopharma has also hired Rick Morgan, who will serve as the company’s new chief scientific officer. Morgan was recently the senior vice president of immunogenetics at Editas Medicine.

Beam Therapeutics

Beam Therapeutics has named Amy Simon as chief medical officer. Simon was most recently vice president of clinical development at Alnylam Pharmaceuticals.

Boundless Bio

Boundless Bio has found its new vice president of discovery and translational development in Shailaja Kasibhatla. Kasibhatla comes to Boundless from Bristol Myers Squibb, where she was senior director of translational development.

Carmot Therapeutics

Manu Chakravarthy, former chief medical officer for Axcella Health, has been named chief medical officer and executive vice president of R&D at Carmot Therapeutics.

Codagenix

Codagenix has made three new appointments to its senior management team, including Lisa Runco to director of operations, Sally Yang to associate director of regulatory affairs and Lasmy Tea to associate director of clinical project management. Runco previously served as the company’s director of R&D finance and project management, Yang was most recently the associate director of regulatory program management at Synchrogenix and Tea was formerly a clinical trial project manager at Alucent Biomedical.

Delix Therapeutics

Mark Rus has been named chief executive officer of Delix Therapeutics. Rus was previously group vice president of neuroscience at Shire Pharmaceuticals.

Fresenius Kabi

Michael Sen has been named CEO of Fresenius Kabi. Prior to this appointment, Sen was executive adviser to the CEO at Siemens.

Immunicum

Erik Manting has taken the helm of Immunicum as its newest CEO. Manting was most recently CEO of DCprime. Immunicum has also named Alex Karlsson-Parra, adjunct professor at Sweden’s Uppsala University, as chief scientific officer. Jeroen Rovers also recently joined Immunicum as its chief medical officer. Most recently, Rovers was chief medical officer at DCprime.

Innovative Cellular Therapeutics

Eugene Kennedy has been appointed chief medical officer of Innovative Cellular Therapeutics. Prior to joining Innovative, Kennedy was chief medical officer of Lumos Pharma.

Lundbeck

Tarek Samad has signed on with Lundbeck as senior vice president of head of research. Most recently, Samad was chief scientific officer at Immunitas Therapeutics.

Lyell Immunopharma

Richard Sherry has been appointed senior vice president, tumor infiltrating lymphocyte specialist and clinical lead of Lyell Immunopharma. Sherry most recently served as research physician and attending surgeon in the surgery branch at the NCI Center for Cancer Research.

Minovia Therapeutics

Alan Jacobs, former chief medical officer at Aspire Health Science, has been named chief medical officer of Minovia Therapeutics.

Panbela Therapeutics

Garry Weems has been appointed vice president of clinical development and medical affairs at Panbela Therapeutics. Previously, Weems was senior director of clinical development at Cerecor.

Peptilogics

Biotechnology company Peptilogics has appointed David Huang to senior vice president and chief medical officer. Huang was recently the chief medical officer of X-Biotix Pharmaceuticals. Peptilogics has also named Nick Nystrom as senior vice president of computing and data. Nystrom recently served as chief scientist at the Pittsburgh Supercomputing Center.

PharmaTher

PharmaTher has named Maurizio Fava as scientific and clinical adviser. Fava is also currently the psychiatrist-in-chief of the Massachusetts General Hospital and executive director of the Clinical Trials Network and Institute (MGH).

Stealth BioTherapeutics

Stealth BioTherapeutics has promoted Marty Redmon from executive vice president of discovery, development and technical operations to chief R&D officer. Redmon was senior vice president of research, development and technical operations at Precision Dermatology before he joined Stealth in 2015.